Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What does the future hold for ACE inhibitors?

J M Cruickshank1

  • 1Wythenshawe Hospital Wythenshawe, Manchester, UK.

Journal of Human Hypertension
|December 1, 1991
PubMed
Summary

Hypertension increases myocardial infarction (MI) risk more than stroke. Angiotensin-converting enzyme (ACE) inhibitors offer benefits beyond blood pressure reduction, improving overall cardiovascular health in hypertensive patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transversely excited atmospheric CO(2) laser radar with heterodyne detection.

Applied optics·2010
Same author

Are we misunderstanding beta-blockers.

International journal of cardiology·2007
Same author

New guidelines on hypertension.

Lancet (London, England)·2006
Same author

The hydration structure of guanidinium and thiocyanate ions: implications for protein stability in aqueous solution.

Proceedings of the National Academy of Sciences of the United States of America·2003
Same author

Renoprotection with antihypertensive agents.

Lancet (London, England)·2002
Same author

Beta-adrenergic blocking drugs in the treatment of hypertension.

Blood pressure·2002

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Research

Background:

  • Myocardial infarction (MI) is the leading cause of death in hypertensive patients, significantly more common than stroke.
  • While lowering blood pressure reduces stroke incidence, its effect on MI is less pronounced, suggesting other cardiovascular risk factors are involved.
  • Traditional antihypertensive agents may not adequately address co-existing risk factors like obesity, lipid disorders, and insulin resistance, and some may even exacerbate them.

Purpose of the Study:

  • To evaluate the role of various antihypertensive agents in managing hypertension and associated cardiovascular risks.
  • To identify antihypertensive medications that offer benefits beyond blood pressure reduction, addressing the broader coronary risk profile.
  • To explore the specific advantages of ACE inhibitors in improving quality of life and cardiovascular outcomes in hypertensive individuals.

Main Methods:

  • Comparative analysis of antihypertensive drug classes (beta-blockers, diuretics, ACE inhibitors) regarding their impact on stroke and MI incidence.
  • Assessment of the effects of these agents on associated cardiovascular risk factors and patient quality of life.
  • Review of clinical evidence supporting the use of ACE inhibitors for specific cardiovascular conditions and risk factor modification.

Main Results:

  • Lowering blood pressure significantly reduces stroke but has a limited impact on MI rates.
  • Certain antihypertensive drugs, like potassium-losing diuretics, may increase the risk of sudden death and MI in some patient groups.
  • ACE inhibitors demonstrate potential for improving quality of life, positively impacting coronary risk factors, and offering benefits in conditions like left ventricular hypertrophy and post-MI remodeling.

Conclusions:

  • There is a need for antihypertensive agents that are effective, well-tolerated, and improve the overall coronary risk profile.
  • ACE inhibitors show promise as a preferred treatment option due to their multifaceted benefits, including improving cardiovascular risk factors and patient quality of life.
  • ACE inhibitors offer significant advantages in managing hypertensive patients, particularly those with impaired left ventricular function, hypertrophy, and those at risk of adverse cardiac remodeling post-MI.

Related Experiment Videos